Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | MAOA | P21397 | 2/20 | 0.61 |
| ▸ | MAOB | P27338 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18493706 | 1.00 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL29438821 | 0.98 | CHRM2 (0.70) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL230222 | 0.98 | CHRM2 (0.70) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL25211342 | 0.95 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| Zinc Ion SCHEMBL30205248 | 0.95 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| Zinc Ion SCHEMBL30442739 | 0.95 | CHRM2 (0.68) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| Anthracene SCHEMBL5346466 | 0.90 | CHRM2 (0.58) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL9777455 | 0.89 | CHRM2 (0.61) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL5569292 | 0.89 | L3MBTL1 (0.62) | CHRM2MAOAMAOBSMN1; SMN2KDM4E | |
| SCHEMBL3314110 | 0.89 | L3MBTL1 (0.62) | CHRM2MAOAMAOBSMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3613435-A1 | CHEMOKINE RECEPTOR CXCR4 INHIBITORS FOR TREATING AND/OR PREVENTING CHRONIC OBSTRUCTIVE PULMONARY DISEASE | UNIVERSITE DE BORDEAUX (FR) | 2020-02-26 | — | — | EP | claimed |
| US-9901616-B2 | Apoptosis-targeting nanoparticles | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2018-02-27 | — | — | US | claimed |
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University of Georgia Foundation, Inc. (US) | 2014-10-09 | — | — | US | claimed |
| EP-2750662-A1 | APOPTOSIS-TARGETING NANOPARTICLES | University Of Georgia Research Foundation, Inc. (US) | 2014-07-09 | — | — | EP | claimed |
| WO-2013033513-A1 | APOPTOSIS-TARGETING NANOPARTICLES | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | WO | claimed |
| US-20240122922-A1 | Methods Of Treating Cancer With Transmembrane Protein 16F (TMEM16F) Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-04-18 | — | — | US | disclosed |
| EP-4340835-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| EP-4340896-A1 | METHODS AND COMPOSITIONS FOR TREATING OCULAR NEOVASCULAR DISEASE | METANOIA BIO INC. (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023129086-A2 | MICRON-SCALE BIOCOMPATIBLE MATERIALS THAT CAN BIND TO NEGATIVELY CHARGED BIOMEMBRANE BEARING SPECIES | ORTA DOĞU TEKNİK ÜNİVERSİTESİ (TR) | 2023-07-06 | — | — | WO | disclosed |
| WO-2023056302-A1 | RADIOCONJUGATES TARGETING GRP78 FOR USE IN THE TREATMENT OF CANCER | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| WO-2023028613-A2 | RADIOIMMUNOCONJUGATES TARGETING PHOSPHATIDYLSERINE FOR USE IN THE TREATMENT OF CANCER | ACTINIUM PHARMACEUTICALS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| EP-3044338-B1 | METHODS FOR EVALUATING AND TREATING WALDENSTROM'S MACROGLOBULINEMIA | DANA FARBER CANCER INST INC (US) | 2021-11-24 | — | — | EP | disclosed |
| US-20090036416-A1 | Novel CXCR4 Antagonist and Use Thereof | KYOTO UNIVERSITY (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-1970062-A1 | NOVEL CXCR4 ANTAGONIST AND USE THEREOF | Kyoto University (JP) | 2008-09-17 | — | — | EP | disclosed |
| EP-1970062-A1 | NOVEL CXCR4 ANTAGONIST AND USE THEREOF | Kyoto University (JP) | 2008-09-17 | — | — | EP | disclosed |
| JP-2007176876-A | NEW CXCR4 ANTAGONIST AND APPLICATION THEREOF | KYOTO UNIV | 2007-07-12 | — | — | JP | disclosed |
| WO-2007074871-A1 | NOVEL CXCR4 ANTAGONIST AND USE THEREOF | KYOTO UNIVERSITY (JP) | 2007-07-05 | — | — | WO | disclosed |
| US-7179616-B1 | Method for detecting phosphatidylserine on the surface of cells | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050148086-A1 | Fluorescent sensor for phosphate ion and phosphorylated peptide | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1484614-A1 | FLUORESCENT SENSOR FOR PHOSPHATE ION AND PHOSPHORYLATED PEPTIDE | Japan Science and Technology Corporation (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140303081-A1 | APOPTOSIS-TARGETING NANOPARTICLES | AIFM1, BAX, BCL2 | CHRM2 4856/4885MAOA 4131/4885MAOB 4657/4885 |
| US-20050148086-A1 | Fluorescent sensor for phosphate ion and phosphorylated peptide | ACP1, PTMS, SLC34A1 | CHRM2 3424/4885MAOA 4144/4885MAOB 4310/4885 |
| US-20090036416-A1 | Novel CXCR4 Antagonist and Use Thereof | CXCR4, CXCR1, CXCL12 | CHRM2 1935/4885MAOA 4742/4885MAOB 4777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.